Fishman Jay A Ltd. MI lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 49,075 shares of the medical technology company’s stock after selling 350 shares during the quarter. Stryker Corporation makes up about 1.4% of Fishman Jay A Ltd. MI’s portfolio, making the stock its 19th biggest holding. Fishman Jay A Ltd. MI’s holdings in Stryker Corporation were worth $6,970,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Stryker Corporation by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock valued at $3,341,643,000 after acquiring an additional 657,656 shares during the last quarter. BlackRock Inc. boosted its position in shares of Stryker Corporation by 5.2% during the 2nd quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock valued at $3,208,017,000 after acquiring an additional 1,139,082 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Stryker Corporation by 0.5% during the 1st quarter. Wellington Management Group LLP now owns 4,569,118 shares of the medical technology company’s stock valued at $601,525,000 after acquiring an additional 24,139 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Stryker Corporation by 6.3% during the 1st quarter. Geode Capital Management LLC now owns 2,786,406 shares of the medical technology company’s stock valued at $366,255,000 after acquiring an additional 166,133 shares during the last quarter. Finally, Jensen Investment Management Inc. boosted its position in shares of Stryker Corporation by 9.9% during the 2nd quarter. Jensen Investment Management Inc. now owns 2,220,791 shares of the medical technology company’s stock valued at $308,201,000 after acquiring an additional 200,192 shares during the last quarter. 74.13% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now directly owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.40% of the stock is currently owned by corporate insiders.
Stryker Corporation (NYSE:SYK) traded down $0.18 during mid-day trading on Monday, hitting $156.00. The stock had a trading volume of 20,962 shares, compared to its average volume of 1,303,827. The firm has a market capitalization of $58,448.43, a P/E ratio of 24.75, a P/E/G ratio of 2.46 and a beta of 0.79. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61.
Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The company’s revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.39 earnings per share. equities research analysts expect that Stryker Corporation will post 6.47 EPS for the current fiscal year.
Several research analysts have recently weighed in on SYK shares. Morgan Stanley reissued an “overweight” rating and set a $160.00 price target (up previously from $155.00) on shares of Stryker Corporation in a research report on Monday, July 10th. BMO Capital Markets reaffirmed a “hold” rating and issued a $140.00 target price on shares of Stryker Corporation in a research report on Tuesday, July 11th. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a research report on Monday, July 17th. Royal Bank Of Canada upped their target price on shares of Stryker Corporation from $140.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Stryker Corporation and gave the company a “hold” rating in a research report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $151.52.
ILLEGAL ACTIVITY WARNING: “Fishman Jay A Ltd. MI Sells 350 Shares of Stryker Corporation (SYK)” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/11/06/fishman-jay-a-ltd-mi-sells-350-shares-of-stryker-corporation-syk.html.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.